profit from every $100 of sales.
$0$100
LivaNova
$92.61+2.91% today
+83.6% in 1 year
1-year low $50.451-year high $94.19
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What LivaNova sold, what it kept, and what it did with the cash.
Sales went from $1.02 billion in 2022 to $1.39 billion in 2025, with -$242 million of profit last year.
SalesProfit
LivaNova vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| LivaNova | No profit yet | ||
 Boston Scientific | 22.0× · Fair price | ||
 Koninklijke Philips | 30.0× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 29.1× · Fair price |
AI analysis
An AI analyst reads LivaNova's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 934 | 1,035 | 1,022 | 1,154 | 1,253 | 1,388 | |
| 595 | 706 | 707 | 756 | 853 | 940 | |
| -274 | -1 | 53 | 21 | 129 | 199 | |
| – | – | 31 | 38 | 203 | -112 | |
| -349 | -136 | -86 | 18 | 63 | -242 | |
| -7.18 | -2.68 | -1.61 | 0.32 | 1.16 | -4.45 | |
| 63.7% | 68.2% | 69.2% | 65.5% | 68.1% | 67.7% | |
| -29.3% | -0.1% | 5.2% | 1.9% | 10.3% | 14.4% | |
| -37.3% | -13.1% | -8.4% | 1.5% | 5.0% | -17.5% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 2,400 | 2,201 | 2,295 | 2,430 | 2,506 | 2,606 |
| Cash | 253 | 208 | 214 | 267 | 429 | 636 |
| Total debt | 704 | 284 | 580 | 640 | 677 | 434 |
| Total liabilities | 1,291 | 906 | 1,087 | 1,152 | 1,186 | 1,406 |
| 1,109 | 1,295 | 1,208 | 1,278 | 1,320 | 1,200 | |
| 49 | 51 | 54 | 54 | 55 | 55 | |
| -13.4% | -3.7% | -1.2% | -0.9% | 6.0% | -8.3% | |
| -31.4% | -10.5% | -7.1% | 1.4% | 4.8% | -20.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -79 | 103 | 70 | 75 | 183 | 254 | |
| 35 | 25 | 27 | 35 | 47 | 81 | |
| -114 | 77 | 43 | 40 | 136 | 173 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 9 | 8 | 8 | – | |
| 35 | 41 | 45 | 36 | 34 | 36 |
Valuation
- –
- 22.0×
- –
- 3.3×
- 3.7×
- 29.4×
- –
- 3.4%
- -4.8%
- 0.0%
Profitability
- 67.7%
- 14.4%
- -17.5%
- 16.2%
- 10.2%
- -4.8%
- 9.1%
- 4.3%
- 11.6%
- 13.7%
Growth
- +8.2%
- –
- +27.4%
- –
- +1.9%
Financial health
- -1.8×
- 0.28
- 13.3%
- 4.0×
- 1.33
- 1.11
- 0.57
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 28%of 948
Top 36%of 871
Bottom 39%of 868
Top 31%of 985
What analysts expect
- Average price target
- $75.88
- Range
- $66.00 – $85.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.98 | 0.85 | +15.3% |
| Feb 25, 2026 | 0.86 | 0.80 | +7.5% |
| Nov 5, 2025 | 1.11 | 0.92 | +20.8% |
| Aug 6, 2025 | 1.05 | 0.84 | +25.0% |
| May 7, 2025 | 0.88 | 0.75 | +17.3% |
| Feb 25, 2025 | 0.81 | 0.80 | +1.3% |
| Oct 30, 2024 | 0.90 | 0.71 | +26.8% |
| Jul 31, 2024 | 0.93 | 0.79 | +17.7% |
News
LivaNova PLC Q3 2026 Earnings Call SummaryYahoo Finance · Nov 4, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
25No pass
Philip Fisher
39No pass
Peter Lynch
40No pass
Joel Greenblatt
8No pass
Charlie Munger
33No pass
Terry Smith
27No pass
Questions about LivaNova
Is LivaNova a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the LivaNova AI analysis
What does LivaNova do?
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. It is in Medical - Devices, based in London, United Kingdom, with 3,300 employees.
Does LivaNova pay a dividend?
No. LivaNova does not pay a dividend at the moment.
Is LivaNova stock halal?
Yes. LivaNova passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
How has LivaNova stock done over the past year?
Up 83.6% over the past twelve months, to $92.61. It traded between $50.45 and $94.19, close to its high.
Who are LivaNova's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with LivaNova's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.